The Number 1 Forum for Life Science IP and Regulatory Professionals
This industry premier life science legal event will gather the leading pharmaceutical and biotech professionals for 3 days of practical discussion on the protection of pharmaceutical drugs based on patent and regulatory exclusivities.
Attend this face-to-face industry summit and have candid discussions with the European life science intellectual property and regulatory experts. The event allows you to form commercially important business relationships, whilst forming a life science legal strategy for 2024 and beyond.
Once again, this year’s summit will host the pre-event SPC & PTE Forum 2024, allowing a mixed audience of in-house counsels, private practice members and key regulators to discuss the strategies and updates concerning SPCs and PTEs. Add this to your registration and form a comprehensive exclusivity strategy for 2024.
DOWNLOAD THE 2024 EVENT AGENDA TODAY
Highlights for 2024 Include
- A review of the latest decisions regarding the SPC waiver and its impact upon your generic and innovator life science exclusivity strategy.
- Discover the intersection between regulatory and IP law with industry-led sessions on: clinical trials, data exclusivity, a Tecfidera case law review and the Pharmaceutical Strategy for Europe.
- Understand the requirements for patentability within the life sciences industry with panel sessions on patent quality, G2/21, enablement and the PTAB.
- Discuss the ways in which the UPC is impacting your life science strategy with an industry-led session and judges panel.
DOWNLOAD THE 2024 EVENT AGENDA
After a huge meeting in 2023, the Life Sciences Strategy Summit on IP & Exclusivity is returning to Munich again to review the latest Regulatory Exclusivity Strategies and legal challenges for pharmaceutical, biotech & medical device companies.
The 2024 event agenda is now ready! Fill out this short form to recieve your copy featuring a star-studded line-up of 45+ speakers.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick above.
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.
2024 EVENT AGENDA IS NOW READY
SPC AND PTE FORUM 2023 (9TH OCTOBER)
Supplementary Protection Certificate's (SPCs) and Patent Term Extensions (PTEs) are a fundamental way in which European law compensates biopharmaceutical companies for their loss in exclusivity rights over a 20-year patent period. This exclusive event workshop will bring together the leading in-house counsel, private practitioners
Discover the latest trends and case studies within European SPC law and understand how this will affect your IP strategy and regulators to discuss the leading trends within SPC/PTE trends from filing to litigation.
PART 1
- Discover the latest trends and case studies within European SPC law and understand how this will affect your IP strategy
PART 2
- Understand the proposed changes to SPCs under the new UPC system and analyse whether a unitary SPC can be utilised
PART 3
- Learn from a wider discussion of PTE extension trends in USA, China, South Korea and Japan
2024 PARTNERS
PLATINUM PARTNERS
Fish & Richardson
Website: https://www.fr.com/industries/life-sciences/
Fish & Richardson has represented pioneering life science innovators from our earliest days. We work closely with life sciences companies to help them achieve their strategic IP goals through acquisition, partnering, licensing, financing, and enforcement. We do this by bringing a unique holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Maiwald Intellectual Property
Website: https://www.maiwald.eu/en/
As one of Germany’s largest and best-known firms in the field of intellectual property (IP), providing optimal services to our clients is of paramount importance to us. Our team comprising about 250 people in Munich and Düsseldorf works closely with each other and with foreign associates, always with an eye to the client’s particular needs, regardless of the particular industry or type of company, whether start-up, medium-sized firm or large corporation, in Germany and worldwide. We at Maiwald will do everything to ensure that all your IP matters are handled with competence and commitment.
You can rely on Maiwald’s wide-ranging expertise. We provide a full range of services covering all aspects of IP law. Our highly qualified patent attorneys and attorneys-at-law unite all of the most important skills one would expect of an interdisciplinary team: sound legal knowledge, business proficiency and a broad range of technical and scientific know-how. And, it goes without saying, absolute professionalism, efficiency and close attention to the needs of each individual client. So you may be assured of receiving the best possible advice on all IP-related issues based on our proven competence and industry knowledge.
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
GOLD PARTNERS
Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.
Clifford Chance
Website: https://www.cliffordchance.com/home.html
Clifford Chance is one of the world’s pre-eminent law firms, with significant depth and range of human and IT resources across five continents. The firm is always striving to exceed the expectations of its clients, which includes banks and other financial institutions, corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not-for-profit organisations. Providing the highest quality advice and legal insight, Clifford Chance prides itself on its approachable, team-based and tech-savvy way of working.
Gemini Law
Website: http://www.geminilaw.com/
Gemini attorneys are among the most experienced and successful at helping manufacturers of biopharma products navigate IP barriers to access the U.S. market. Gemini has particular expertise in patent strategy and litigation relating to biosimilar, biobetter, generic and 505(b)(2) products, as well as collateral issues concerning the Hatch Waxman and BPCIA regulatory schemes. Gemini is also very experienced in counseling early-stage biotech companies to optimize patent portfolios and mitigate the risk posed by competitors’ IP, as well as IP issues related to licensing and development transactions. Gemini offers “end to end” counseling on IP issues in support of biopharma product development and launch in the U.S., including:
- Litigation risk mitigation and avoidance
- Patent & trade secret design-around strategies
- Patent portfolio optimization
- Biosimilar (BPCIA) litigation & regulatory strategy
- Hatch Waxman litigation & regulatory strategy
- "Biobetter" & "fast follow-on" product litigation & regulatory strategy
- Pharmaceutical device-related litigation & regulatory strategy
- IP & regulatory issues concerning healthcare AI
- CREATES Act requests & litigation
- Section 1782 discovery requests for use in foreign litigation
- Global coordination of litigation strategy concerning biosimilar, generic and biobetter products
- Patent landscaping and freedom-to-operate opinions
- IP-related licensing, development & manufacturing transactions
- Lobbying and legislative initiatives relating to the BPCIA and Hatch Waxman laws
Hoffmann Eitle PartmbB
Website: https://www.hoffmanneitle.com/en
Please visit our website for more information.King & Wood Mallesons
Website: https://www.kwm.com/uk/en/home.html
Please visit our website for more information.Potter Clarkson
Website: https://www.potterclarkson.com/
Leading European intellectual property law firm, Potter Clarkson helps companies, organisations, and individuals across all sectors of business to understand, create, protect, and defend the commercial value of their innovations anywhere in the world. Its 200-strong specialist team of patent attorneys, trade mark attorneys, litigators, and licensing specialists, operate from dedicated offices in the UK, Sweden, and Denmark.
Recognised as one of Europe’s leading intellectual property law firms, Potter Clarkson is particularly well-known for its deep expertise in resolving life science disputes, its contentious practice routinely conducting high-profile litigation in key jurisdictions around the world as well as before the EPO, and now the UPC, with multiple actions currently on foot before this important new court.
Schertenleib Avocats
Website: https://schertenleib-avocats.com/en/equipe/denis-schertenleib/
Please visit our website for more information.Simmons & Simmons
Website: https://www.simmons-simmons.com/en/expertise/service/intellectual-property/patents
Our international Patent team seamlessly integrates the specialized expertise of a boutique practice with the extensive service offerings of a major international firm. Recognized in the market for our high-calibre clients and active involvement in leading global patent cases, we stand as a trusted force in the European legal landscape; with offices and well established patent experts in London, Amsterdam, Paris, Munich and Milan and with Pharma & Biotech as one of our firm’s four core sectors.
Leveraging our extensive experience, we adeptly guide clients through specialised procedures, including infringement seizures, preliminary injunctions, patent infringement actions, patent nullification actions, and non-infringement declarations. With over 45 years at the forefront of IP law and practice, our international reputation is anchored in a pre-eminent track record in complex patent litigation (alongside a market-leading IP transactions and regulatory practices). Our comprehensive suite of services offers a "one-stop-shop" for pharma and biotech clients needing advice and strategic partnership on patents and other areas of IP.
Simmons and Simmons has played a pivotal role in the development of the Unified Patent Court (UPC) system. Our partner, Kevin Mooney, is acknowledged as one of the "fathers of the UPC", if not “Mr UPC”. Positioned at the forefront of every aspect of the new system, we don't just advise on the law – we actively shape it.
Sterne Kessler
Website: https://www.sternekessler.com/
Please visit our website for more information.Taylor Wessing LLP
Website: https://www.taylorwessing.com/en/about-us
Please visit our website for more information.Venable LLP
Website: https://www.venable.com/
Venable LLP is an American Lawyer Global 100 law firm headquartered in Washington, DC that serves as primary counsel to a worldwide clientele of large and mid-sized organizations, nonprofits, high-net-worth entrepreneurs, and other individuals. With more than 850 professionals across the country, including in California, Colorado, Delaware, Florida, Illinois, Maryland, New York, Virginia, and Washington, DC, the firm strategically advances its clients' objectives in the United States and around the globe. Venable advises clients on a broad range of business and regulatory law, legislative affairs, complex litigation, and the full range of intellectual property disciplines. For more information, please visit https://www.venable.com/
SOLUTION PARTNERS
RWS
Website: https://www.rws.com/intellectual-property-services/
RWS is the world’s leading provider of technology-enabled language, content management, and intellectual property services. With over 60 years of experience in the IP arena RWS expertise in patent translations, foreign filing and IP research services is unrivalled.
Clients trust RWS to deliver high-quality translations in a format ready for filing, in compliance with national filing formalities and maintaining exactly the same protective scope as the original.
RWS also helps clients simplify and streamline their internal processes, by providing flexible, cost-effective foreign filing and renewals services dramatically reducing the administrative burden associated with EP validations, PCT national phase entries and direct filings.
When it comes to research, RWS offers the most robust intellectual property (IP) researcher services and tools available. From our market leading patent research database, PatBase, to the world’s most comprehensive set of IP search offerings from desk based analysts to crowdsearch.
RWS clients include many of the world's largest filers including 19 of the top 20 applicants at the World Intellectual Property Organization and 16 of the top 20 applicants at the European Patent Office.
Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
Become A Partner
Interested in how you can get involved with Life Sciences Strategy Summit on IP & Exclusivity 2024?
Based on your objectives, we can create bespoke packages for you. From presenting your expertise on stage to partnering with us to deliver networking activities. Partner with us in 2024 to showcase your brand and make valuable new connections. Opportunities include thought leadership, branding, and networking.
Discuss your objectives with Duncan Henderson, Commercial Partnerships Director, [email protected]
Don't Just Take Our Word For It, Here Is What The Community Has To Say
Great event with insightful presentations and panels. I learned a lot and met very knowledgeable people. The event was well organized.
Very interesting topics were discussed that were spot-on relevant for my daily work as a life science patent attorney.
Good overview of the ongoing challenges and proposals in EU with regards to UPC, SPC and Regulatory, preempting Generics to roll up their sleeves.
The Summit gave a good overview and an opportunity to hear and discuss the latest insights on IP and exclusivity for Life Science. I liked that all relevant parties were present to share their views.
A really well organised event with an excellent selection of relevant talks and great networking opportunities.
This is a serious conference and was attended by IP attorneys and in house counsels. The topics taken were very relevant and it was a very good experience. The round table discussion was also good.
The speakers were well coordinated so little overlap but good integration of the topics. I came away with a better understanding of the topics presented.
Excellent speakers and highly relevant topics made for a thoroughly worthwhile conference.
Informative breadth of multidisciplinary topics which are rarely fused together into a single conference elsewhere. Provided useful insights from the perspectives of different domains.
I have already recommended the event to colleagues. I particularly liked the presentations on the SPC waivers and on the proposals for unitary SPCs and the amended SPC Regulations as well as the national examiners' session.
I had the privilege of attending the Life Sciences Strategy Summit 2023, and it was an invaluable experience. The event brought together a diverse and knowledgeable community of professionals, fostering insightful discussions on the latest trends and strategies in the life sciences industry. The engaging sessions and networking opportunities provided a unique platform to connect with experts and peers, contributing to a richer understanding of the field. I'm grateful for the opportunity to be part of this vibrant community, and I look forward to future events.
The event was perfectly suitable for the professionals who have expertise in life science. All speakers and attendees were highly qualified and experienced in diverse fields of IP.
A fantastic forum with expert speakers and attendees gathered to learn about the most important topics in IP and exclusivity in the life sciences. The schedule provides plants of networking opportunities to supplement the excellent subject matter content.
This event is bringing together in-house counsels and law professionals from the main countries and is focusing directly on the current trending topics in the IP-Pharma industry, which is very valuable to both sides.
Kisaco's event on Life Sciences is becoming a real central moment for the IP European community. The organisation is great and the panels very well organized and dedicated. The participants are the best players in the field.
LIFE SCIENCES PATENT ADVISORY BOARD
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Ewan Nettleton
Tessa M. Malamud-Cohen
Paki Banky
Corinna Sundermann
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Toni Santamaria
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Adrian Spillmann
Julia Pike
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Philip Caramanica
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Ewan Nettleton
Tessa M. Malamud-Cohen
Paki Banky
Corinna Sundermann
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Toni Santamaria
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Adrian Spillmann
Julia Pike
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Christoph Rehfuess
Philip Caramanica
LIFE SCIENCES STRATEGY SUMMIT 2023 COMMUNITY
From our advisory board and speakering faculty to our media and strategic partners, our series wouldn't be possible without the contributions of Our esteemed community of in-house IP counsel, private practice and regulatory leaders.
2023 SPEAKERS
Adrian Chew
Adrian Spillmann
Agathe Michel-De-Cazotte
Agnieszka Deeg-Tyburska
Ana Lopez Lozano
Andre Andrade
Andreas Robinson
Anna Wolters-Hoehne
Anna is a highly experienced patent litigator advising primarily life sciences clients in global patent disputes. With about 20 years of practice in leading and coordinating high profile patent cases Anna develops both offensive and defensive patent strategies for her clients to protect their product portfolio nationally and in an international context.
Anna’s long-standing expertise covers patent infringement and preliminary injunction proceedings as well as patent damages proceedings before the German courts. She also advises on national compulsory licence cases and nullity actions as well as EPO opposition proceedings and the UPC. Anna regularly coordinates international patent disputes and advises clients in particular from the innovative pharmaceutical and medical device industries.
Axel Berger
Betsy Flanagan
Bianca Vos
Boris Andrejas
Brian Coggio
Cecile Teles
Cecile is Head Patent Attorney at Zentiva. She has over a decade of experience in the pharmaceutical industry.
Cecile is uniquely experienced and knowledgeable in the pharma space as she has experience in-house at an elite innovator company (Sanofi), biologics (Merck Serono), and extensive generic experience she gained as Zentiva.
Cecile is an enthusiastic manager of her team and was a key member of the IP team in leading the transformation of Zentiva into an independent and competitive generic company after divestment from Sanofi.
Cecile is a qualified European Patent Attorney. She also holds a certificate from CEIPI in patent litigation and most recently completed her diploma as a Master of Laws in France.
Charlotte Weekes
Christina Brown-Marshall
Christina Thomson
Christof Bull
Christoph Rehfuess
Claudia Milbradt
Corinna Sundermann
Denis Schertenleib
Dolores Cassidy
Dolores Cassidy, B.Sc. Ph.D., graduated from University College Dublin with a Ph.D. in Physical Chemistry. In 1998 she joined the Intellectual Property Office of Ireland as a Patent Examiner, with particular responsibility for the examination of Supplementary Protection Certificates (SPCs). In 2021 she was promoted to the position of Head of Patent/SPC Examination at the Irish Office.
Dorian Immler
Eduardo Hallak
Eduardo Hallak is one of the founding partners at Licks Attorneys and one of our leaders at the Sao Paulo office. For more than a decade, he has been working as a litigator before state and federal courts in Brazil in several complex disputes and leading cases involving Patent law, competition, and regulatory compliance, most of them pursuing the interests of clients in the area of life sciences. He also has extensive practice in trademark litigation as well as technology transfer contracts, working together with multinational clients to establish strong brand protection and licensing programs in the country. Mr. Hallak also currently teaches IP litigation in the Post-Graduation course at the prestigious Pontifical Catholic University of Rio de Janeiro (PUCRJ), has taught Civil Procedure at the at the Brazilian Association of IP Agents (ABAPI), and is often invited to lecture on procedural and strategic aspects of IP litigation, in addition to being a member of the Special Commission on Mediation of the Rio de Janeiro Chapter of the Brazilian Bar Association (OABRJ) and the Enforcement Committee of INTA.
Elodie Ferraty
Eva Ehlich
Filipe Pedro
Florian Bechtel
Fritz Gerritzen
Gemma Barrett
Gemma is an experienced and trusted advisor for some of the world’s leading life sciences and chemical companies. Her background in biochemistry means she specialises in complex technical disputes in the life sciences sector. She has more than fifteen years’ experience advising clients in patent litigation matters before the English Courts including securing preliminary injunctions. She is also experienced in advising on global cross-border litigation, and coordinating worldwide litigation, working closely with multi-disciplinary teams in the defence and enforcement of patent portfolios. She has developed innovative and successful strategies, often combining patent and regulatory law, to assist pharmaceutical companies in the enforcement of their rights.
Geoff Biegler
Ha Kung Wong
Ha Kung Wong has over 20 years of experience practicing general intellectual property law with an emphasis on complex patent and trade secret litigation as well as IP transactions and contract negotiations for mergers, acquisitions, and collaborations in pharmaceuticals, biologics, and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, allergy eye drops, anti-epileptic drugs, anti-tussive, injectable microspheres, RNAi products, and other pharmaceuticals. Mr. Wong also has extensive experience with Inter Partes Review, Post Grant Review, intellectual property counseling, pharmaceutical regulatory counseling, pre-suit investigations, licensing, and due diligence.
Mr. Wong has his BS with high distinction in Chemistry and his BS in Biochemistry from the University of Illinois Urbana-Champaign and his JD, cum laude, from the University of Notre Dame. Mr. Wong is currently an elected member of the Venable Board, is an Advisory Board Member for the Center for Biosimilars, is Treasurer, Executive Committee member, and Board Trustee for the Foundation for Advancement of Diversity in IP Law (FADIPL) and serves as faculty for the National Institute of Trial Advocacy (NITA) and Lawline.
Hilary Pioro
Isabelle Gundel
Isobel Barry
James Horgan
Jiri Slavik
Judith Krens
Julia Pike
Since March 2020, Julia has been the Global Head of IP for Sandoz. In her previous roles with Sandoz, she has had a leading role in the first wave of US biosimilars litigation, including the first litigations on critical aspects of the governing legislation (the Biologics Price Competition and Innovation Act or BPCIA), culminating in the landmark US Supreme Court decision, Sandoz v Amgen.
Since leaving private practice at Corrs Chambers Westgarth, Julia has been in-house counsel for many years including at Mayne Pharma and Hospira Inc before joining Sandoz in 2008. While there, she has taken on roles in European public affairs and led Sandoz’s global IP litigation function as Global Head of IP Litigation. Through those roles, she has maintained a keen interest in IP strategy and litigation worldwide, including cases arising under the Hatch-Waxman and BPCIA legislation in the US, PM(NOC) regulations in Canada and litigation arising from patent linkage systems around the world.
Karin Pramberger
Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva. She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam.
Katherine Helm
Katie Rooth
Kaushal Joshi
Kora Knuchel
Laila Beynon
Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT.
Lora Green
Prior to joining Gemini, Lora was a senior partner at Wilson, Sonsini, Goodrich & Rosati, as part of the firm’s PTAB practice group.
Before entering private practice, Lora was a Lead Administrative Patent Judge at the U.S. Patent & Trademark Office, as well as a primary patent examiner in the pharmaceutical and biotechnology examining groups. While at the USPTO, she managed post-grant review proceedings, such as inter partes and post grant reviews.
Manja Epping
As a lawyer specialising in pharmaceutical and IP law, Manja has been advising pharmaceutical and biotechnology companies, medical device manufacturers, and food producers on all matters relating to intellectual property and regulatory questions for many years. One of her areas of expertise is regulatory data and market protection as well as orphan drug exclusivity, where she has a track record of representing clients before German and EU courts. Another focus of her practice involves advising clients on complex contractual projects, in particular, research and development cooperations, manufacturing agreements, distribution agreements and licence agreements.
Marco Stief
Margaret O'Gara
Margaret is a French and European patent attorney currently heading IP at a late development stage biotech in Paris, called Nanobiotix.
She started her professional career as a researcher in the pharma industry in the UK and France, before moving into patents in 2004.
Since then she has worked both in-house and in IP firms and spent nearly ten years with Santarelli before taking the IP position at Nanobiotix early 2020. Margaret has considerable experience in all aspects of European patent prosecution, and post grant proceedings, as well as strategies for filing new applications . She is interested in data exclusivity and prolonging the protection of innovative products.
Maria Lamottke
Marius-Benjamin Schneider
Dr Martijn de Lange
Martin Schmidt
Max Haedicke
Michal Porubsky
Mortiz Ammelberg
Nicholas Mitrokostas
Nick is the Managing Partner of the Boston office and an experienced Life Sciences trial attorney who focuses on representing innovator companies in intellectual property, trade secret, licensing and antitrust disputes. A litigator known for his trial skills, Nick has been lead counsel and gone to trial in dozens of ANDA and BPCIA litigations and has extensive experience representing clients in the pharmaceutical, biotechnology, and medical device industries in federal and state courts as well as before the Patent Trial and Appeal Board (PTAB). Nick also has expertise in counseling emerging and small and mid-cap Life Sciences companies in late stage drug development on issues pertaining to patent and regulatory exclusivities including patent term extension (PTE), patent listing requirements, and pre-commercial and launch assessments and litigation risks.
Dr Oliver Werner
Patrick Heckeler
Paul Calvo
Pedro Roman
Petra Bohanec Grabar
Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.
Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.
Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.
Roberto Romandini
Roberto Romandini obtained his law degree from the University of Pisa and his LL.M. degree from the University of Munich, where he specialized in patent law. He completed his Ph.D. thesis on the patentability of human stem cells at the Max Planck Institute in Munich before practicing IP law at a leading IP law firm in Milan for 5 years. From 2013 he was a Senior Research Fellow at the Max Planck Institute for Innovation and Competition in Munich. Since 2019 he has been a legal member at the Boards of Appeal at the EPO.
Robin Ellis
Sabine Klepsch
Sara Burhart
Sherry Yao
Stefania Bergia
Stefanie Kies
Stephen Reese
Suzanne Renes
Suzanne graduated Cum Laude from Amsterdam University College in 2015 with a BSc in Biomedical Sciences. In 2016 she graduated from University College London with an MSc in Pharmaceutical Formulation and Entrepreneurship. She is a qualified Dutch and European Patent Attorney that started her career in the Pharma team at NLO in 2018. Since January 2022 she has been employed in the Ablynx team of Sanofi in Ghent, where she has been working as a patent attorney specializing in immunoglobulin single variable domains (camelid-derived VHH). In her free time, she enjoys learning new languages, playing badminton and dancing salsa.
Tamaris Bucher
Tamaris is a Principal Patent Attorney at Novartis. She has gained extensive experience in pharmaceuticals in her almost ten years at Novartis, as well as from a previous role at a patent law firm in Basel.
She specialises in patent matters relating to antibody technology and cell & gene therapies. She has expertise in patent prosecution and SPC issues, as well as a keen interest in following legal developments in these areas.
Tamaris is both a registered European Patent Attorney and Swiss Patent Attorney. Additionally, she has a background in Australian patent law, having completed a Master of Industrial Property at the University of Technology, Sydney.
Tobias Wuttke
BOOK YOUR PLACE TODAY
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Registration ends on
— —
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 1 - In-House€599Super Super Early Bird Pricing - Register before 28th June to save €400Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 1 - In-House€799 + VATSuper Early Bird Pricing - Register before 2nd August to save €200Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 1 - In-House€899 + VATEarly Bird Pricing - Register before 6th September to save €100Exclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 1 - In-House€999 + VATStandard PricingExclusively For In-House Counsels2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 2 - Law Firms€1399 + VATSuper Super Early Bird Pricing - Register before 28th June to save €900Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 2 - Law Firms€1699 + VATSuper Early Bird Pricing - Register before 2nd August save €600Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 2 - Law Firms€1999 + VATEarly Bird Pricing - Register before 6th September to save €300Exclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 2 - Law Firms€2299 + VATStandardExclusively For Law Firms2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Saturday, June 29, 2024Tier 3 - Service Providers/Vendors€2099 + VATSuper Super Early Bird Pricing - Register before 28th June to save €1400Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, June 29, 2024 to Saturday, August 3, 2024Tier 3 - Service Providers/Vendors€2499 + VATSuper Early Bird Pricing - Register before 2nd August to save €1000Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, August 3, 2024 to Saturday, September 14, 2024Tier 3 - Service Providers/Vendors€2999 + VATEarly Bird Pricing - Register before 6th September save €500Exclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Saturday, September 14, 2024 to Thursday, October 10, 2024Tier 3 - Service Providers€3499 + VATStandard PricingExclusively For Service Providers2 Day In-Person Conference PassYou can add our pre-event workshop as an add-on during registration
- Wednesday, May 1, 2024 to Thursday, October 10, 2024SPC & PTE Forum - PRE DAY ONLY€799 + VAT
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.